ACHN -- "we have all 3 parts of the HCV solution and we can it develop in-house"
I hope everyone understands what this means. It means:
we have all three parts of an HCV solution and we will not accept a lowball buyout offer. Though we may consider a buyout at say $5-6 billion. We have --
(a) a proven NS3/4A PI (2684, sovaprevir),
(b) a proven NS5A inhibitor (3102).
(c) a safe & efficacious NS5B nucleoside inhibitor (3422) now being tested in the clinic!!
If you continue to short this stock, be prepared for a lot more pain!!
Gilead has a much better drug in singular form, so.....maybe thats why insiders have sold you out, and why Associates Gp Qvt, a major owner of Achillion Pharmaceuticals, recently disposed of 1,819,551 shares of the company. The disposals took place at prices ranging from $7.57 to $7.85 per share, on June 16, 2014.
ACHN becomes an attractive buy-out candidate when its nuke 3422 is de-risked in clinical trials. It would allow the acquirer to compete with Gilead by targeting a 4-6 week cure versus Gilead's 8-12 week cure by using a 3-drug combo that includes 3422.